Array BioPharma, Inc. (NASDAQ:ARRY) is scheduled to present at the JP Morgan 28th Annual Healthcare Conference on Wednesday, January 13. The conference will take place at the Westin St. Francis in San Francisco, California. The company will be represented by Array BioPharma Chief Executive Officer Robert Conway. Mr. Conway will begin his presentation at 3:00 pm PT that afternoon. Interested parties may listen to a live webcast of the event online at http://www.arraybiopharma.com/.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
Array BioPharma Inc. (Array) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. In addition, pharmaceutical and biotechnology companies collaborate with the Company to discover and develop drug candidates across a range of therapeutic areas. The Company has seven wholly owned programs in its development pipeline: ARRY-403, a glucokinase activator for Type 2 diabetes; ARRY-162, a MEK inhibitor for rheumatoid arthritis and cancer; ARRY-380, an ErbB-2 inhibitor for breast cancer; ARRY-520, a KSP inhibitor for acute myeloid leukemia and multiple myeloma; ARRY-614, a p38/Tie 2 dual inhibitor for myelodysplastic syndrome; ARRY-543, an ErbB family (ErbB-2 / EGFR) inhibitor for solid tumors, and ARRY-797, a p38 inhibitor for subacute pain and cancer supportive care indications.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
